Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...
Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...
LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
DexCom is building increasingly user-friendly devices that continuously monitor blood glucose levels, and a new collaboration between DexCom and Google could lead to the smallest such devices yet.
Zacks Investment Research on MSN
DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal
DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, ...
Roughly 1.25 million Americans have Type 1 diabetes, so chances are you know somebody whose pancreas is taking the world’s longest lunch break. That person may be you. As it happens, there has never ...
Dexcom provided a look at new data for the upcoming generation of its continuous glucose monitoring sensor. Presenting at the J.P. Morgan Healthcare Conference, the details were pulled from a large ...
More than 34 million Americans have diabetes and an additional 88 million are at risk of developing the disease, according to the American Diabetes Association. In this world of data, automation, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback